Early-phase research is a strategy-driven first step in the development of new drugs and medical devices. In drug development, pre-clinical studies are designed to provide detailed information on dosing and toxicity levels. This phase of development allows for the selection of the best novel agents to enter the clinical trial phase and to minimize failure in development. Pre-clinical evaluation is highly important for the development of innovative medical devices, as safety and efficacy testing enable the design of studies that fulfill regulatory requirements. DIA provides a forum, network, and resources for facilitating collaboration and insights exchange for professionals involved in pre-clinical and early-phase research.
Pharmacometrics: The Already-Present Future of Precision Pharmacology
The use of mathematical modeling to represent, analyze, make predictions or providing information on data obtained in drug research and development has made pharmacometrics an area of great prominence and importance. In this review, we describe the meaning, history, and development of pharmacometrics, analyzing the challenges faced in the training of professionals.
Submit an Abstract
Submit an abstract for an existing or future event on any topic that advances the pharmaceutical, biotechnology, medical device, and related fields.
Content Highlights
-
A Platform Approach to mRNA Product Development and Regulation: Necessary and Feasible Now
Read Now -
Issues, Ideas and Initiatives: Proposals from the DIA/Harvard-MIT CRS Cell and Gene Therapy Executive Roundtable
Read Now -
Life Sciences 2024ward: Translational Medicine Q&A: What’s in Store for 2024?
Read Now
Learn More
Discovery and Pre-Clinical Phases Online Course
In this module, learners focus on how companies advance potential drug candidates through the earliest stages of research, from therapeutic target to readiness for clinical studies.
Drug Development and Lifecycle Management eLearning Program
Understand how companies structure their efforts and utilize their resources to improve the odds of successful development, and potentially minimize the risks associated with shepherding a new drug candidate through the development process.